Table 1.
ATX-V5 Med has lysoPLD activity.
| ATX-V5 Med | Heated-inactive ATX-V5 Med | |||||
|---|---|---|---|---|---|---|
|
|
||||||
| 0 μM LPC | 10 μM LPC | 50 μM LPC | 200 μM LPC | 0 μM LPC | 50 μM LPC | |
| 16:1LPA | 2.4±0.6 | 6.6±0.3 | 32.2±2.8 | 51.0±5.1 | 1.0±0.7 | 0.9±0.1 |
| 16:0LPA | 7.0±1.3 | 52.9±9.4 | 369±22.9 | 559±65.6 | 6.9±4.3 | 0.0±0.0 |
| 18:2LPA | 2.8±1.9 | 3.5±0.9 | 24.7±2.1 | 41.4±3.8 | 1.2±0.8 | 0.5±0.3 |
| 18:1LPA | 9.2±2.9 | 12.1±1.8 | 61.7±4.8 | 92.5±8.5 | 2.8±0.9 | 3.4±0.7 |
| 18:0LPA | 11.5±5.1 | 11.1±1.5 | 81.1±3.9 | 117.6±10.1 | 3.6±1.6 | 0.0±0.0 |
|
| ||||||
| Total LPA | 33.0±10.1 | 86.2±13.0 | 568±34.0 | 852±92.6 | 15.3±7.7 | 4.8±1.1 |
ATX-V5 Med and heated-inactive ATX-V5 Med were incubated with different concentration of egg LPC for 30 min. Lipids in the medium were then isolated and concentration of LPA species (fmol/ml) were measured by LC/MS/MS. The data represents mean± S.D. from three independent experiments.